HALOZYME THERAPEUTICS INC (HALO) Stock Price, Quote, News and Overview
NASDAQ:HALO - Nasdaq - US40637H1095 - Common Stock - Currency: USD
HALO Quote, Performance and Key Statistics
HALOZYME THERAPEUTICS INC
NASDAQ:HALO (2/3/2025, 2:38:26 PM)
56.515
-0.12 (-0.22%)
The current stock price of HALO is 56.515 USD. In the past month the price increased by 18.47%. In the past year, price increased by 68.17%.
HALO Latest News, Press Releases and Analysis
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a candidate for high growth investors. Here's why.
A fundamental and technical analysis of (NASDAQ:HALO): HALOZYME THERAPEUTICS INC (NASDAQ:HALO) may be suited for high growth investing, we'll explore why in this article.
NASDAQ:HALO—A High-Growth Stock Gearing Up for Its Next Upward Move.
Based on fundamental and technical analysis of NASDAQ:HALO we ask: Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Is a Standout High-Growth Stock in a Consolidation Phase.
In the world of growth stocks, NASDAQ:HALO shines as a value proposition.
HALOZYME THERAPEUTICS INC was identified as an affordable growth stock. NASDAQ:HALO is showing great growth, but also scores well on profitability. At the same time it seems to be priced reasonably.
In a market where value is scarce, NASDAQ:HALO offers a refreshing opportunity with its solid fundamentals.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
CHMP Issues Positive Opinion for Subcutaneous RYBREVANT®(amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company,...
BeiGene Stock Meets 80-Plus RS Rating Benchmark
One key metric to look for in a stock is an 80-plus Relative Strength Rating. BeiGene stock just hit that mark, with a jump to 84 Wednesday.
HALO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.93 | 338.51B | ||
| AMGN | AMGEN INC | 15.05 | 155.45B | ||
| GILD | GILEAD SCIENCES INC | 22.36 | 123.43B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 925.76 | 121.59B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.72 | 73.48B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.55B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.55B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.89B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.00B | ||
| NTRA | NATERA INC | N/A | 23.38B | ||
| BIIB | BIOGEN INC | 8.74 | 20.79B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.73 | 15.99B |
Related stock screener links
About HALO
Company Profile
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. The company is headquartered in San Diego, California and currently employs 373 full-time employees. The company went IPO on 2003-01-30. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on reducing treatment burden for patients. The company also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The firm has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies. The company markets and sells Hylenex recombinant, which is a formulation of rHuPH20. The company markets and sells its proprietary product XYOSTED for SC administration of testosterone replacement therapy (TRT) in adult males.
Company Info
HALOZYME THERAPEUTICS INC
12390 El Camino Real
San Diego CALIFORNIA 92121-1345 US
CEO: Helen I. Torley
Employees: 373
Company Website: https://www.halozyme.com/
Investor Relations: https://ir.halozyme.com/
Phone: 18587948889
HALO FAQ
What is the stock price of HALO?
The current stock price of HALO is 56.515 USD.
What is the symbol for HALOZYME THERAPEUTICS INC stock?
The exchange symbol of HALOZYME THERAPEUTICS INC is HALO and it is listed on the Nasdaq exchange.
On which exchange is HALO stock listed?
HALO stock is listed on the Nasdaq exchange.
Is HALO a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for HALO, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of HALO.
Does HALO stock pay dividends?
HALO does not pay a dividend.
When does HALO stock report earnings?
HALO will report earnings on 2025-02-25, after the market close.
What is the Price/Earnings (PE) ratio of HALO?
The PE ratio for HALO is 14.91. This is based on the reported non-GAAP earnings per share of 3.79 and the current share price of 56.515 USD.
What is the Short Interest ratio of HALO stock?
The outstanding short interest for HALO is 7.55% of its float.
HALO Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to HALO. When comparing the yearly performance of all stocks, HALO is one of the better performing stocks in the market, outperforming 88.41% of all stocks.
HALO Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to HALO. HALO has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
HALO Financial Highlights
Over the last trailing twelve months HALO reported a non-GAAP Earnings per Share(EPS) of 3.79. The EPS increased by 55.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 41.43% | ||
| ROA | 18.53% | ||
| ROE | 86.69% | ||
| Debt/Equity | 3.32 |
HALO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 76% to HALO. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of 51.47% and a revenue growth 20.86% for HALO